COMPANY
Atticus Pharma
NIH awards 2
- NIH award 1R44AR087266-01A1 FY2026: $1,007,121 awarded for that fiscal year; activity R44 (SBIR); PI DRAGANSKI, ANDREW R; recipient as written: ATTICUS PHARMA INC, GREENVILLE, SC. Phase 2: Development of an endocanna source ↗
- NIH award 2R44DK129147-02 FY2026: $965,708 awarded for that fiscal year; activity R44 (SBIR); PI DRAGANSKI, ANDREW R; recipient as written: ATTICUS PHARMA INC, GREENVILLE, SC. Phase II: Optimization of a nanoparticle source ↗
Funding and NIH signals
- NIH award NIH awarded $1.01M (SBIR Phase II 1R44AR087266-01A1, new, notice Sep 19, 2026); 2 NIH awards totaling $1.97M in the last 12 months. NIH RePORTER 1R44AR087266-01A1 (Sep 19, 2026)
Evidence (2 events)
- Sep 19, 2026 · NIH RePORTER 1R44AR087266-01A1
Organization: ATTICUS PHARMA INC; City/State: GREENVILLE, SC; Project number: 1R44AR087266-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-19; FY total cost (award amount): 1007121; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Phase 2: Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus; Organization type: Domestic For-Profits - Aug 13, 2026 · NIH RePORTER 2R44DK129147-02
Organization: ATTICUS PHARMA INC; City/State: GREENVILLE, SC; Project number: 2R44DK129147-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 965708; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Phase II: Optimization of a nanoparticle-based topical PDE5i formulation for treatment of erectile dysfunction; Organization type: Domestic For-Profits
- Sep 19, 2026 · NIH RePORTER 1R44AR087266-01A1